Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Wednesday. They currently have a $9.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 70.45% from the company’s current price.

Separately, BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Four analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has an average rating of “Buy” and a consensus target price of $9.00.

Pieris Pharmaceuticals (PIRS) opened at 5.28 on Wednesday. The stock’s market capitalization is $233.95 million. The company has a 50 day moving average of $5.72 and a 200-day moving average of $5.72. Pieris Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $6.58.

TRADEMARK VIOLATION NOTICE: “Pieris Pharmaceuticals, Inc. (PIRS) Rating Reiterated by HC Wainwright” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/18/pieris-pharmaceuticals-inc-pirs-rating-reiterated-by-hc-wainwright.html.

In other Pieris Pharmaceuticals news, insider Allan Reine bought 65,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, with a total value of $313,300.00. Following the completion of the acquisition, the insider now owns 45,000 shares of the company’s stock, valued at $216,900. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James A. Geraghty bought 10,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were acquired at an average cost of $4.82 per share, for a total transaction of $48,200.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $48,200. The disclosure for this purchase can be found here. 4.05% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter worth $661,000. Sphera Funds Management LTD. raised its holdings in shares of Pieris Pharmaceuticals by 10.0% during the second quarter. Sphera Funds Management LTD. now owns 1,100,000 shares of the biotechnology company’s stock worth $5,566,000 after purchasing an additional 100,000 shares during the period. Creative Planning raised its holdings in shares of Pieris Pharmaceuticals by 8.3% during the second quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock worth $329,000 after purchasing an additional 5,000 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $132,000. Finally, Rhumbline Advisers acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $184,000. 50.50% of the stock is currently owned by institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.